The ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 73, Issue 5, 2000, Pages 883-896

  Whelan III, Joseph G ^a   Vlahos, Nikos F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assisted reproductive technologies; Controlled ovarian hyperstimulation; In vitro fertilization; Ovarian hyperstimulation syndrome; Ovulation induction; Paracentesis; Polycystic ovarian syndrome

Indexed keywords

INFUSION FLUID; PLASMA SUBSTITUTE;

ANESTHESIA; ASCITES; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FLUID THERAPY; HOSPITALIZATION; HUMAN; INTENSIVE CARE; OVARY HYPERSTIMULATION; PARACENTESIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYNDROME; THROMBOSIS;

EID: 0034002108     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)00491-X     Document Type: Article

References (82)

1. Cluroe A.D., Synek B.J. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 27:1995;344-346.
2. Lyons C.A., Wheeler C.A., Frishman G.N., Hackett R.J., Seifer D.B., Haning R.V. Jr. Early and late presentation of the ovarian hyperstimulation syndrome two distinct entities with different risk factors . Hum Reprod. 9:1994;792-799.
3. Golan A., Ron-el R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome an update review . Obstet Gynecol Surv. 44:1989;430-440.
4. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment [published erratum appears in Fertil Steril 1993;59:1334] . Fertil Steril. 58:1992;249-261.
5. Tollan A., Holst N., Forsdahl F., Fadnes H.O., Oian P., Maltau J.M. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol. 162:1990;554-558.
6. Goldsman M.P., Pedram A., Dominguez C.E., Ciuffardi I., Levin E., Asch R.H. Increased capillary permeability induced by human follicular fluid a hypothesis for an ovarian origin of the hyperstimulation syndrome [see comments] . Fertil Steril. 63:1995;268-272.
7. Paulson R.J., Do Y.S., Hsueh W.A., Eggena P., Lobo R.A. Ovarian renin production in vitro and in vivo characterization and clinical correlation . Fertil Steril. 51:1989;634-638.
8. Lightman A., Tarlatzis B.C., Rzasa P.J., Culler M.D., Caride V.J., Negro-Vilar A.F., et al. The ovarian renin-angiotensin system renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid . Am J Obstet Gynecol. 156:1987;808-816.
9. Sealey J.E., Glorioso N., Itskovitz J., Laragh J.H. Prorenin as a reproductive hormone. New form of the renin system. Am J Med. 81:1986;1041-1046.
10. Glorioso N., Atlas S.A., Laragh J.H., Jewelewicz R., Sealey J.E. Prorenin in high concentrations in human ovarian follicular fluid. Science. 233:1986;1422-1424.
11. Derkx F.H., Alberda A.T., Zeilmaker G.H., Schalekamp M.A. High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 94:1987;4-9.
12. Robertson A.L., Khairallah P.A. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res. 31:1972;923-931.
13. Ong A.C., Eisen V., Rennie D.P., Homburg R., Lachelin G.C., Jacobs H.S., et al. The pathogenesis of the ovarian hyperstimulation syndrome (OHS) a possible role for ovarian renin . Clin Endocrinol (Oxf). 34:1991;43-49.
14. Navot D., Margalioth E.J., Laufer N., Birkenfeld A., Relou A., Rosler A., et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 48:1987;57-61.
15. Morris R.S., Wong I.L., Kirkman E., Gentschein E., Paulson R.J. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod. 10:1995;1355-1358.
16. Loret de Mola J.R., Baumgardner G.P., Goldfarb J.M., Friedlander M.A. Ovarian hyperstimulation syndrome pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-alpha cannot predict its occurrence . Hum Reprod. 11:1996;1377-1380.
17. Abramov Y., Schenker J.G., Lewin A., Friedler S., Nisman B., Barak V. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod. 11:1996;1381-1386.
18. Knox G.E. Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 118:1974;992-994.
19. Knox G.E., Dowd A.J., Spiesel S.A., Hong R. Antihistamine blockade of the ovarian hyperstimulation syndrome. II. Possible role of antigen-antibody complexes in the pathogenesis of the syndrome. Fertil Steril. 26:1975;418-421.
20. Gergely R.Z., Paldi E., Erlik Y., Makler A. Treatment of ovarian hyperstimulation syndrome by antihistamine. Obstet Gynecol. 47:1976;83-85.
21. Schenker J.G., Polishuk W.Z. The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 6:1976;47-52.
22. Pride S.M., Yuen B.H., Moon Y.S., Leung P.C. Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol. 154:1986;1155-1160.
23. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V. Jr, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
24. Krasnow J.S., Berga S.L., Guzick D.S., Zeleznik A.J., Yeo K.T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome a preliminary report . Fertil Steril. 65:1996;552-555.
25. Abramov Y., Barak V., Nisman B., Schenker J.G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 67:1997;261-265.
26. Lee A., Christenson L.K., Stouffer R.L., Burry K.A., Patton P.E. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil Steril. 68:1997;305-311.
27. Levin E.R., Rosen G.F., Cassidenti D.L., Yee B., Meldrum D., Wisot A., et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 102:1998;1978-1985.
28. Yan Z., Weich H.A., Bernart W., Breckwoldt M., Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab. 77:1993;1723-1725.
29. Neulen J., Yan Z., Raczek S., Weindel K., Keck C., Weich H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells importance in ovarian hyperstimulation syndrome . J Clin Endocrinol Metab. 80:1995;1967-1971.
30. Balasch J., Reverter J.C., Fabregues F., Tassies D., Ordinas A., Vanrell J.A. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 66:1996;608-613.
31. Todorow S., Schricker S.T., Siebzehnruebl E.R., Neidhardt B., Wildt L., Lang N. Von Willebrand factor an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome . Hum Reprod. 8:1993;2039-2046.
32. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol. 138:1991;213-221.
33. Kodama H., Fukuda J., Karube H., Matsui T., Shimizu Y., Tanaka T. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril. 64:1995;1207-1209.
34. Kodama H., Fukuda J., Karube H., Matsui T., Shimizu Y., Tanaka T. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril. 66:1996;417-424.
35. Navot D., Relou A., Birkenfeld A., Rabinowitz R., Brzezinski A., Margalioth E.J. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 159:1988;210-215.
36. Delvigne A., Demoulin A., Smitz J., Donnez J., Koninckx P., Dhont M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization a Belgian multicentric study. I. Clinical and biological features . Hum Reprod. 8:1993;1353-1360.
37. Forman R.G., Frydman R., Egan D., Ross C., Barlow D.H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization a European series and a proposal for prevention [see comments] . Fertil Steril. 53:1990;502-509.
38. Mizunuma H., Andoh K., Yamada K., Takagi T., Kamijo T., Ibuki Y. Prediction and prevention of ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified follicle-stimulating hormone therapy. Fertil Steril. 58:1992;46-50.
39. Mordel N., Schenker J.G. Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod. 8:1993;2009-2014.
40. Haning R.V. Jr, Austin C.W., Carlson I.H., Kuzma D.L., Shapiro S.S., Zweibel W.J. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril. 40:1983;31-36.
41. Enskog A., Henriksson M., Unander M., Nilsson L., Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 71:1999;808-814.
42. Blankstein J., Shalev J., Saadon T., Kukia E.E., Rabinovici J., Pariente C., et al. Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles . Fertil Steril. 47:1987;597-602.
43. MacDougall M.J., Tan S.L., Jacobs H.S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;597-600.
44. Buyalos R.P., Lee C.T. Polycystic ovary syndrome pathophysiology and outcome with in vitro fertilization [see comments] . Fertil Steril. 65:1996;1-10.
45. Lewis C.G., Warnes G.M., Wang X.J., Matthews C.D. Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. Fertil Steril. 53:1990;1097-1099.
46. Herman A., Ron-El R., Golan A., Raziel A., Soffer Y., Caspi E. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Fertil Steril. 53:1990;92-96.
47. Gustafson O., Carlstrom K., Nylund L. Androstenedione as a predictor of ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;918-921.
48. Chenette P.E., Sauer M.V., Paulson R.J. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization. Fertil Steril. 54:1990;858-863.
49. Asch R.H., Li H.P., Balmaceda J.P., Weckstein L.N., Stone S.C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology definition of high risk groups . Hum Reprod. 6:1991;1395-1399.
50. Juliusson S., Aldenborg F., Enerback L. Proteinase content of mast cells of nasal mucosa; effects of natural allergen exposure and of local corticosteroid treatment [published erratum appears in Allergy 1995;50:462]. Allergy. 50:1995;15-22.
51. Nakamura Y., Smith M., Krishna A., Terranova P.F. Increased number of mast cells in the dominant follicle of the cow relationships among luteal, stromal, and hilar regions . Biol Reprod. 37:1987;546-549.
52. Zaidise I., Friedman M., Lindenbaum E.S., Askenazi R., Peretz B.A., Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 15:1983;55-60.
53. Erlik Y., Naot Y., Friedman M., Ben-David E., Paldi E. Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol. 53:1979;580-582.
54. Urman B., Pride S.M., Yuen B.H. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod. 7:1992;213-217.
55. Trounson A., Wood C., Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril. 62:1994;353-362.
56. Buvat J., Marcolin G., Guittard C., Herbaut J.C., Louvet A.L., Dehaene J.L. Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization superiority of human chorionic gonadotropin over oral progesterone . Fertil Steril. 53:1990;490-494.
57. Imoedemhe D.A., Sigue A.B., Pacpaco E.L., Olazo A.B. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril. 55:1991;328-332.
58. Lewit N., Kol S., Manor D., Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome a case-control study . Hum Reprod. 11:1996;1399-1402.
59. Friedman C.I., Schmidt G.E., Chang F.E., Kim M.H. Severe ovarian hyperstimulation following follicular aspiration. Am J Obstet Gynecol. 150:1984;436-437.
60. Golan A., Ron-El R., Herman A., Weinraub Z., Soffer Y., Caspi E. Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril. 50:1988;912-916.
61. Garcia J., Jones G.S., Acosta A.A., Wright G.L. Jr. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil Steril. 36:1981;565-572.
62. Fakih H., Bello S. Ovarian cyst aspiration a therapeutic approach to ovarian hyperstimulation syndrome . Fertil Steril. 58:1992;829-832.
63. Asch R.H., Ivery G., Goldsman M., Frederick J.L., Stone S.C., Balmaceda J.P. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome [see comments]. Hum Reprod. 8:1993;1015-1020.
64. Shoham Z., Weissman A., Barash A., Borenstein R., Schachter M., Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program a prospective, randomized, placebo-controlled study . Fertil Steril. 62:1994;137-142.
65. Isipyk A.Z., Kahraman S., Vicdan K., Alaybeyoglou L., Ozgun O.D., Polat G., et al. Intravenous albumin combined with low dose human chorionic gonadotropin and late step-down administration of menotropins are effective in prevention of severe ovarian hyperstimulation syndrome in high-risk patients in an in vitro fertilization program. Middle East Fertility Society Journal. 2:1997;238-241.
66. Lewit N., Kol S., Ronen N., Itskovitz-Eldor J. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil Steril. 66:1996;654-656.
67. Ng E., Leader A., Claman P., Domingo M., Spence J.E. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme [see comments]. Hum Reprod. 10:1995;807-810.
68. Pattinson H.A., Hignett M., Dunphy B.C., Fleetham J.A. Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril. 62:1994;1192-1196.
69. Shaker A.G., Zosmer A., Dean N., Bekir J.S., Jacobs H.S., Tan S.L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome [see comments]. Fertil Steril. 65:1996;992-996.
70. Borenstein R., Elhalah U., Lunenfeld B., Schwartz Z.S. Severe ovarian hyperstimulation syndrome a reevaluated therapeutic approach . Fertil Steril. 51:1989;791-795.
71. Pride S.M., Ho Yuen B., Moon Y.S. Clinical, endocrinologic, and intraovarian prostaglandin F responses to H-1 receptor blockade in the ovarian hyperstimulation syndrome studies in the rabbit model . Am J Obstet Gynecol. 148:1984;670-674.
72. Beerendonk C.C., van Dop P.A., Braat D.D., Merkus J.M. Ovarian hyperstimulation syndrome facts and fallacies . Obstet Gynecol Surv. 53:1998;439-449.
73. Zosmer A., Katz Z., Lancet M., Konichezky S., Schwartz-Shoham Z. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril. 47:1987;524-526.
74. Padilla S.L., Zamaria S., Baramki T.A., Garcia J.E. Abdominal paracentesis for the ovarian hyperstimulation syndrome with severe pulmonary compromise. Fertil Steril. 53:1990;365-367.
75. Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome [published erratum appears in Fertil Steril 1990;54:957]. Fertil Steril. 53:1990;933-935.
76. Rizk B., Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 6:1991;1082-1087.
77. Rinaldi M.L., Spirtos N.J. Chest tube drainage of pleural effusion correcting abdominal ascites in a patient with severe ovarian hyperstimulation syndrome a case report [see comments] . Fertil Steril. 63:1995;1114-1117.
78. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome [see comments]. Hum Reprod. 7:1992;180-183.
79. Reed A.P., Tausk H., Reynolds H. Anesthetic considerations for severe ovarian hyperstimulation syndrome. Anesthesiology. 73:1990;1275-1277.
80. Tan S.L., Balen A., el Hussein E., Campbell S., Jacobs H.S. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization a prospective randomized study . Fertil Steril. 58:1992;378-383.
81. Fukaya T., Chida S., Terada Y., Funayama Y., Yajima A. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril. 61:1994;561-564.
82. Beck D.H., Massey S., Taylor B.L., Smith G.B. Continuous ascitic recirculation in severe ovarian hyperstimulation syndrome. Intensive Care Med. 21:1995;590-593.